Design Therapeutics, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. The filing was signed August 14, 2023. Design Therapeutics is a clinical-stage biotechnology company developing GeneTAC small-molecule candidates for diseases caused by inherited nucleotide repeat expansions. It has no approved products and reported no product revenue.
Financial results and position
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Research and development expense | $17.1 million | $11.3 million | $32.8 million | $20.1 million |
| General and administrative expense | $5.5 million | $4.3 million | $11.5 million | $9.0 million |
| Total operating expenses | $22.6 million | $15.6 million | $44.2 million | $29.0 million |
| Operating loss | $22.6 million | $15.6 million | $44.2 million | $29.0 million |
| Other income, net | $2.7 million | $0.6 million | $5.0 million | $0.7 million |
| Net loss | $19.9 million | $15.0 million | $39.2 million | $28.3 million |
| Basic and diluted loss per share | $0.36 | $0.27 | $0.70 | $0.51 |
- Revenue and margins: No product revenue was reported. Profit margins are not meaningful for this pre-commercial company.
- Cash flow: Net cash used in operating activities was $31.2 million for the first six months of 2023, versus $22.3 million in the comparable 2022 period. Investing activities provided $31.7 million, primarily reflecting investment maturities exceeding purchases; financing activities provided $0.2 million.
- Liquidity: Cash and cash equivalents were $27.2 million and investment securities were $275.9 million at June 30, 2023, totaling $303.1 million, versus $330.4 million at December 31, 2022. Management said available resources should fund planned operations for more than 12 months after issuance of the statements; this is based on assumptions and does not fund candidates through approval.
- Balance sheet: Total assets were $311.6 million; total liabilities were $14.8 million and stockholders’ equity was $296.8 million. No borrowings or debt balance was disclosed. Liabilities include operating lease obligations; the lease is with an entity managed by the executive chairperson.
- Investment securities were available-for-sale and principally U.S. Treasury and government agency securities, certificates of deposit, and money market funds. Unrealized losses were attributed primarily to interest-rate changes; the company reported no credit-loss allowance.
Changes versus comparable periods
- Q2 operating expenses rose $7.0 million year over year; first-half expenses rose $15.2 million. R&D increases reflected DT-216 clinical development, early-stage programs, and higher staffing and stock-based compensation.
- First-half net loss increased $11.0 million year over year. Higher operating expenses were partly offset by substantially higher interest and other income.
- First-half operating cash use increased $8.9 million. The decrease in cash and investments from year-end primarily reflected funding operations; investment maturities and purchases affect cash balances but not the combined liquidity figure in the same way.
- Accumulated deficit reached $150.0 million at June 30, 2023, compared with $110.8 million at December 31, 2022.
Pipeline, outlook and material risks
- DT-216 for Friedreich ataxia (FA): The filing reports initial multiple-ascending-dose Phase 1 results announced in August 2023, after quarter-end. The 29-participant study was fully enrolled and ongoing at the August 7 data cutoff. The filing describes DT-216 as generally well tolerated, with no treatment-related serious adverse events or discontinuations; all adverse events were mild or moderate. Five cases of injection-site thrombophlebitis occurred across dose cohorts. Blinded safety data were reported.
- In the 300 mg cohort, exploratory skeletal-muscle FXN mRNA increased a mean 30% from baseline two days after the third weekly dose, statistically significant versus placebo (p<0.05); dose-response and tissue exposure-response trends were also significant. FXN protein results were inconclusive because of high measurement variability. These are preliminary, exploratory findings and may change with further analysis.
- The company stopped dose escalation at 300 mg and shifted from the previously planned Phase 2 path to an improved DT-216 formulation, citing concern that thrombophlebitis could worsen with higher doses and repeated administration. It expected bridging nonclinical studies, a new multiple-dose Phase 1 trial in the second half of 2024, and initial data in the first half of 2025. These are forward-looking targets, not assurances.
- Other programs: DT-168 for Fuchs endothelial corneal dystrophy (FECD) was nominated in December 2022; the company planned to submit an IND in the second half of 2023. For myotonic dystrophy type 1 (DM1), it expected to complete IND-enabling work and submit an IND in 2024. Other programs remained in discovery or nonclinical development.
- Operating outlook: Management expects losses and expenses to increase as it advances programs, conducts studies and trials, and expands clinical, regulatory, manufacturing and operational capabilities. The company expects to need substantial additional capital to develop candidates through approval; future equity financing could dilute shareholders, while collaborations could require surrendering rights.
- Key risks: Clinical and regulatory uncertainty; DT-216 formulation, safety and development delays; reliance on third-party manufacturers and research organizations; single-source supply and a previously reported vial-stopper issue that briefly delayed DT-216 supply; competition, including approved FA therapy omaveloxolone; and the possibility that capital needs exceed available resources. Management cited macroeconomic and market conditions as potential financing risks.
- Contingencies and governance: The company reported no material contingent liabilities and no litigation likely to have a material adverse effect. It disclosed related-party lease and consulting arrangements. Disclosure controls were assessed as effective at the reasonable-assurance level, with no material quarterly change in internal control over financial reporting reported.
Investor verification priorities
- Review the full MAD Phase 1 data and subsequent safety follow-up, especially thrombophlebitis incidence, attribution, severity and implications for the improved formulation.
- Confirm progress and timing of DT-216 bridging studies and the planned 2024 Phase 1 restart and 2025 data, including any changes to dose, route or trial design.
- Assess whether FXN mRNA response translates into durable protein or clinical benefit; distinguish exploratory biomarker results from established efficacy.
- Track quarterly operating cash use, investment balances and updated cash runway against development plans and financing needs.
- Check whether the planned DT-168 IND submission and DM1 IND-enabling milestones were achieved, and monitor manufacturing and third-party supply execution.
- Evaluate dilution and governance exposure, including the unused ATM program and related-party arrangements; verify any changes in outstanding shares or financing plans.